IBIO

0.80010.11%
MB

Martin B. Brenner

CEO, Chief Scientific Officer & Director

Dr. Martin B. Brenner DVM., Ph.D., is Chief Executive Officer of iBio, Inc. from June 27, 2023 and serves as its Director since June 01, 2024. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 2023 to June 27, 2023 and has been its Chief Scientific Officer since January 18, 2021. He had been Senior Vice President and Chief Scientific Officer at Pfenex Inc. since March 18, 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. Dr. Brenner has led a successful career Heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly, Pfizer and Merck. Most recently, Dr. Brenner served as the CSO at Recursion Pharmaceuticals since 2017 until 2018, a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics from 2016 to 2017, a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. In addition, Dr. Brenner was the Senior Director and Head of cardiovascular, renal and metabolism (CVRM) biosciences at AstraZeneca, during which time he developed a new research strategy and reorganized the departments into lean and agile teams. Since 2012 until 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner was an Associate Research Fellow at Pfizer since 2009 until 2012 where he led the Islet Biology and In Vivo Pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group. Since 2013 until 2016, he was Executive Director Diabetes & NASH and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab where he built a biotech unit from scratch focusing his research on Diabetes, nonalcoholic steatohepatitis (NASH) and Diabetic Complications. Dr. Brenner earned his DVM at the Ludwig-Maximilians-University in Munich, Germany and his Ph.D. in Pharmacology at the Veterinary School of Hannover in Hannover, Germany.

Positions